Whether the vaccine will ever be approved is completely open.
(Photo: dpa)
Frankfurt Curevac draws conclusions from the disappointing study results of its Covid-19 vaccine. The Tübingen biotech company gives up its first production partnerships for the manufacture of the vaccine, for which it has not yet had market approval in Europe.
Specifically, the contractual agreements with the chemical company Wacker and the Swiss biopharmaceutical company Celonic will be canceled within the contractually agreed notice period, as Curevac announced on Tuesday. The existing contracts with Rentschler Biopharma and the pharmaceutical company Novartis for the production and formulation of mRNA will not be affected by the adjustment and will continue to exist.
Nothing will change in the cooperation with Bayer: “Our cooperation and service agreement with Bayer is in place,” said a Curevac spokeswoman when asked by the Handelsblatt. Bayer is a strategic partner of Curevac and not part of the external production network.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 6 weeks.
Further
.